Now showing items 1-13 of 13

    • Burning a hole in the budget: tobacco spending and its crowd-out of other goods. 

      Busch, Susan H; Falba, Tracy; Jofre-Bonet, Mireia; Sindelar, Jody L (Appl Health Econ Health Policy, 2004)
      Smoking is an expensive habit. Smoking households spend, on average, more than $US1000 annually on cigarettes. When a family member quits, in addition to the former smoker's improved long-term health, families benefit because ...
    • Cost of capital to the hospital sector. 

      Hassan, M; Morrisey, MA; Sloan, Frank A; Valvona, J (J Health Econ, 1988-03)
      This paper provides estimates of the cost of equity and debt capital to for-profit and non-profit hospitals in the U.S. for the years 1972-83. The cost of equity is estimated using, alternatively, the Capital Asset Pricing ...
    • Cost of innovation in the pharmaceutical industry. 

      DiMasi, Joseph A; Grabowski, Henry G; Hansen, Ronald W; Lasagna, L (J Health Econ, 1991-07)
      The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms. These data were used to estimate the pre-tax average cost of new ...
    • Data Sharing at a Crossroads. 

      Rockhold, Frank Wesley; Nisen, P; Freeman, A (N Engl J Med, 2016-09-22)
    • Does Medicaid pay more to a program of all-inclusive care for the elderly (PACE) than for fee-for-service long-term care? 

      Wieland, Darryl; Kinosian, B; Stallard, Eric; Boland, R (J Gerontol A Biol Sci Med Sci, 2013-01)
      BACKGROUND: In rebalancing from nursing homes (NHs), states are increasing access of NH-certified dually eligible (Medicare/Medicaid) patients to community waiver programs and Programs of All-Inclusive Care for the Elderly ...
    • Economic return of clinical trials performed under the pediatric exclusivity program. 

      Benjamin, Daniel Kelly; Califf, Robert M; Eisenstein, EL; Goldsmith, JV; Grabowski, Henry G; Li, JS; Mangum, B; ... (10 authors) (JAMA, 2007-02-07)
      CONTEXT: In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric ...
    • Effects of teaching on hospital costs. 

      Feldman, RD; Sloan, Frank A; Steinwald, A Bruce (J Health Econ, 1983-03)
      This study estimates effects of undergraduate and graduate medical education on hospital costs, using a national sample of 367 U.S. community hospitals observed in 1974 and 1977. Data on other cost determinants, such as ...
    • Fish is food--the FAO's fish price index. 

      Asche, Frank; Bellemare, MF; Guttormsen, Atle G; Lem, A; Lien, K; Smith, Martin D; Tveterås, S; ... (8 authors) (PLoS One, 2012)
      World food prices hit an all-time high in February 2011 and are still almost two and a half times those of 2000. Although three billion people worldwide use seafood as a key source of animal protein, the Food and Agriculture ...
    • Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. 

      Anstrom, Kevin J; Edwards, R; Eisenstein, EL; Enhanced Recovery Study Group; Gan, Tong Joo; Jin, Juying; Mantyh, Christopher Ritchie; ... (13 authors) (Anesth Analg, 2014-05)
      BACKGROUND: Enhanced recovery after surgery (ERAS) is a multimodal approach to perioperative care that combines a range of interventions to enable early mobilization and feeding after surgery. We investigated the feasibility, ...
    • Returns to R&D on new drug introductions in the 1980s. 

      Grabowski, Henry G; Vernon, John M (J Health Econ, 1994-12)
      This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes ...
    • Spending on postapproval drug safety. 

      Grabowski, Henry G; Kramer, JM; Ridley, David Blaine; Schulman, Kevin Alan; Tilson, HH (Health Aff (Millwood), 2006-03)
      Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ...
    • The distribution of sales revenues from pharmaceutical innovation. 

      Grabowski, Henry G; Vernon, John M (Pharmacoeconomics, 2000)
      OBJECTIVE: This report updates our earlier work on the returns to pharmaceutical research and development (R&D) in the US (1980 to 1984), which showed that the returns distributions are highly skewed. It evaluates a more ...
    • The price of innovation: new estimates of drug development costs. 

      DiMasi, Joseph A; Grabowski, Henry G; Hansen, Ronald W (J Health Econ, 2003-03)
      The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ...